Clinical trial
Immunochemotherapy for Metastatic Renal Cell Carcinoma
NCT00226798 · Rambam Health Care Campus, Other · Unknown status
Key facts
| NCT number | NCT00226798 |
|---|---|
| Title | Immunochemotherapy for Metastatic Renal Cell Carcinoma |
| Official title | Interleukin-2, Interferon Alpha,Capecitabine and Vinblastin for Treatment of Metastatic Renal Cell Carcinoma: A Multicenter Study |
| Lead sponsor | Rambam Health Care Campus, Other |
| Collaborators | Roche Pharma AG Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma Clear Cell |
| Intervention type | Drug |
| Interventions | Capecitabine (Xeloda) |
| Enrollment | 45 |
| Start date | Dec 1, 2003 |
| Completion | Sep 1, 2005 |
| First posted | Sep 27, 2005 |
| Last update posted | Jan 4, 2006 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: